Influenzavirus B Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Influenzavirus B Infections – Pipeline Review, H2 2019’, provides an overview of the Influenzavirus B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenzavirus B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections

– The report reviews pipeline therapeutics for Influenzavirus B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenzavirus B Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenzavirus B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenzavirus B Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenzavirus B Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenzavirus B Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AbbVie Inc

Abhelix LLC

Adimmune Corp

Allergy Therapeutics Plc

Ansun Biopharma Inc

Aphios Corp

AstraZeneca Plc

AusBio Ltd

Biotron Ltd

BlueWillow Biologics Inc

Cidara Therapeutics Inc

Cocrystal Pharma Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

e-Therapeutics Plc

Evotec SE

Evrys Bio

Fujifilm Toyama Chemical Co Ltd

GC Pharma

Imutex Ltd

Inovio Pharmaceuticals Inc

iQur Ltd

Johnson & Johnson

Medicago Inc

Novavax Inc

Osivax SAS

Park Active Molecules

Romark Laboratories LC

Sanofi Pasteur SA

Sciogen Inc

Seqirus Ltd

Serum Institute of India Ltd

Shanghai Institute of Biological Products Co Ltd

Shionogi & Co Ltd

Sinovac Biotech Ltd

Therapeutic Systems Research Laboratories Inc

UMN Pharma Inc

Vacthera BioTech GmbH

Vaxart Inc

Ventaleon GmbH

Viramatix Sdn Bhd

Wuhan Institute of Biological Products Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Influenzavirus B Infections Overview 6

Influenzavirus B Infections Therapeutics Development 7

Influenzavirus B Infections Therapeutics Assessment 16

Influenzavirus B Infections Companies Involved in Therapeutics Development 24

Influenzavirus B Infections Drug Profiles 38

Influenzavirus B Infections Dormant Projects 105

Influenzavirus B Infections Discontinued Products 107

Influenzavirus B Infections Product Development Milestones 108

Appendix 117

List of Tables

“List of Tables

Table 1: Number of Products under Development for Influenzavirus B Infections, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Universities/Institutes, H2 2019

Table 6: Products under Development by Companies, H2 2019

Table 7: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 8: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 9: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 10: Products under Development by Universities/Institutes, H2 2019

Table 11: Number of Products by Stage and Target, H2 2019

Table 12: Number of Products by Stage and Mechanism of Action, H2 2019

Table 13: Number of Products by Stage and Route of Administration, H2 2019

Table 14: Number of Products by Stage and Molecule Type, H2 2019

Table 15: Influenzavirus B Infections – Pipeline by AbbVie Inc, H2 2019

Table 16: Influenzavirus B Infections – Pipeline by Abhelix LLC, H2 2019

Table 17: Influenzavirus B Infections – Pipeline by Adimmune Corp, H2 2019

Table 18: Influenzavirus B Infections – Pipeline by Allergy Therapeutics Plc, H2 2019

Table 19: Influenzavirus B Infections – Pipeline by Ansun Biopharma Inc, H2 2019

Table 20: Influenzavirus B Infections – Pipeline by Aphios Corp, H2 2019

Table 21: Influenzavirus B Infections – Pipeline by AstraZeneca Plc, H2 2019

Table 22: Influenzavirus B Infections – Pipeline by AusBio Ltd, H2 2019

Table 23: Influenzavirus B Infections – Pipeline by Biotron Ltd, H2 2019

Table 24: Influenzavirus B Infections – Pipeline by BlueWillow Biologics Inc, H2 2019

Table 25: Influenzavirus B Infections – Pipeline by Cidara Therapeutics Inc, H2 2019

Table 26: Influenzavirus B Infections – Pipeline by Cocrystal Pharma Inc, H2 2019

Table 27: Influenzavirus B Infections – Pipeline by ContraFect Corp, H2 2019

Table 28: Influenzavirus B Infections – Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Table 29: Influenzavirus B Infections – Pipeline by e-Therapeutics Plc, H2 2019

Table 30: Influenzavirus B Infections – Pipeline by Evotec SE, H2 2019

Table 31: Influenzavirus B Infections – Pipeline by Evrys Bio, H2 2019

Table 32: Influenzavirus B Infections – Pipeline by Fujifilm Toyama Chemical Co Ltd, H2 2019

Table 33: Influenzavirus B Infections – Pipeline by GC Pharma, H2 2019

Table 34: Influenzavirus B Infections – Pipeline by Imutex Ltd, H2 2019

Table 35: Influenzavirus B Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Table 36: Influenzavirus B Infections – Pipeline by iQur Ltd, H2 2019

Table 37: Influenzavirus B Infections – Pipeline by Johnson & Johnson, H2 2019

Table 38: Influenzavirus B Infections – Pipeline by Medicago Inc, H2 2019

Table 39: Influenzavirus B Infections – Pipeline by Novavax Inc, H2 2019

Table 40: Influenzavirus B Infections – Pipeline by Osivax SAS, H2 2019

Table 41: Influenzavirus B Infections – Pipeline by Park Active Molecules, H2 2019

Table 42: Influenzavirus B Infections – Pipeline by Romark Laboratories LC, H2 2019

Table 43: Influenzavirus B Infections – Pipeline by Sanofi Pasteur SA, H2 2019

Table 44: Influenzavirus B Infections – Pipeline by Sciogen Inc, H2 2019

Table 45: Influenzavirus B Infections – Pipeline by Seqirus Ltd, H2 2019

Table 46: Influenzavirus B Infections – Pipeline by Serum Institute of India Ltd, H2 2019

Table 47: Influenzavirus B Infections – Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019

Table 48: Influenzavirus B Infections – Pipeline by Shionogi & Co Ltd, H2 2019

Table 49: Influenzavirus B Infections – Pipeline by Sinovac Biotech Ltd, H2 2019

Table 50: Influenzavirus B Infections – Pipeline by Therapeutic Systems Research Laboratories Inc, H2 2019

Table 51: Influenzavirus B Infections – Pipeline by UMN Pharma Inc, H2 2019

Table 52: Influenzavirus B Infections – Pipeline by Vacthera BioTech GmbH, H2 2019

Table 53: Influenzavirus B Infections – Pipeline by Vaxart Inc, H2 2019

Table 54: Influenzavirus B Infections – Pipeline by Ventaleon GmbH, H2 2019

Table 55: Influenzavirus B Infections – Pipeline by Viramatix Sdn Bhd, H2 2019

Table 56: Influenzavirus B Infections – Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2019

Table 57: Influenzavirus B Infections – Dormant Projects, H2 2019

Table 58: Influenzavirus B Infections – Dormant Projects, H2 2019 (Contd..1), H2 2019

Table 59: Influenzavirus B Infections – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Influenzavirus B Infections, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports